Programs & ResourcesBack

Programs & ResourcesBack

Welcome to the ARESTIN®  Student Access Program

ARESTIN® Student Access is a program sponsored by OraPharma, Inc., the makers of ARESTIN®, and designed with the help of dental educators, to provide dental and dental hygiene students with clinical information and hands-on training in periodontal treatment including ARESTIN® + scaling and root planing (SRP).

faculty

FOR FACULTY
Introduce students to patient selection and periodontal disease treatment that includes  ARESTIN® + SRP when indicated.

Program materials for instructors include PowerPoint® lectures, classwork, laboratory sessions, clinical exercises, and evaluations.

faculty

FOR STUDENTS
Learn about periodontal disease, patient selection, and treatment of periodontal disease that includes ARESTIN® + SRP when indicated.

Program includes classroom lectures, lab work, and clinical experience. Program materials for students include an ARESTIN® Student Trial Kit and reading materials.

The ARESTIN® Student Access Program is sponsored by OraPharma, Inc.  

INDICATION
ARESTIN® (minocycline HCl) Microspheres, 1 mg is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.

IMPORTANT SAFETY INFORMATION
ARESTIN® should not be used in any patient who has a known sensitivity to minocycline or tetracyclines. The use of drugs of the tetracycline class during tooth development may cause permanent discoloration of the teeth, and therefore should not be used in children or in pregnant or nursing women. Hypersensitivity reactions that included, but were not limited to, anaphylaxis, angioneurotic edema, urticaria, rash, swelling of the face and pruritus have been reported with the use of ARESTIN®. In clinical trials, the most frequently reported nondental treatment-emergent adverse events were headache, infection, flu syndrome and pain.

Please read the Full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

MyArestinTM is a trademark and ARESTIN® is a registered trademark of OraPharma, Inc.

This site is published by OraPharma, Inc., which is solely responsible for its contents. It is intended for visitors from the United States.

Manufactured for OraPharma, Inc. ©OraPharma, Inc. 2013   A-1373-12   01/13